Press Release

​FemPulse Corporation announced the issuance of two patents from China and Australia covering methods of stimulation of autonomic nerve plexuses in women. Read the Rest of the Article

FemPulse Corporation announced the first participant has been enrolled in the Company’s clinical trial evaluating physiological responses to therapy delivered with the FemPulse System. Observations from this feasibility study can further help elucidate the mechanisms of action and facilitate tailoring treatment plans for individual patients. Read the Rest of the Article

FemPulse Corporation announced that Donald Deyo, President and CEO, is scheduled to participate in the Entrepreneur Panel I session on bioelectronic medicine in the 2019 Bioelectronic Medicine Forum taking place Thursday, April 4th, in New York City. This is the second annual meeting of the Bioelectronic Medicine Forum, a management and investment conference focused exclusively […]

FemPulse Corporation announced enrollment of first patients at each of the centers participating in the Company’s EVANESCE-OAB™ (Evaluation of a Non-Implanted Electrical Stimulation Continence Device for Overactive Bladder) U.S. clinical trial. This study will evaluate the treatment of OAB in a home or at-work setting using the Company’s proprietary medical device, the FemPulse System. Read […]

FemPulse Corporation is pleased to share the appointment of Dr. Robert Kieval as Chief Scientific and Clinical Officer. Dr. Kieval is a medical technology industry veteran, with over 25 years of experience in innovating, financing, and commercializing novel technologies. Dr. Kieval is responsible for continuing to expand the Company’s significant clinical and scientific evidence portfolio. […]

The FemPulse clinical results were presented at the American Urology Association (AUA) annual meeting in San Francisco. Dr. Suzette Sutherland, University of Washington, presented that primary objectives regarding fit, comfort and safety were met, as well as positive secondary outcomes regarding patient preference, a reduction in incontinence events and an increase in time between voids.

FemPulse Corporation announced completion in the first quarter of 2018 of a private financing round, which will enable acceleration of the development of its novel and proprietary bioelectronic therapy for overactive bladder (OAB) in females. Proceeds will be used for technical and clinical evidence development in preparation for commercialization of the therapy in the US […]

The results of the FemPulse clinical study will be presented at the International Urogynecological Association (IUGA) annual meeting to be held in Vienna, Austria on June 27 – 30, 2018. The invitation provides an opportunity to share the exciting potential of FemPulse with a premier global audience in the field of urogynecology. Dr. Suzette Sutherland, […]

Dr. Suzette Sutherland, University of Washington, Seattle has been invited to make a podium presentation of the FemPulse clinical study results at the American Urology Association (AUA) annual meeting to be held in San Francisco on May 18 – 21, 2018. This invitation reflects well on the clinical and scientific merit of the FemPulse study, […]

FemPulse announced completion of a conversion from its original legal structure, a Limited Liability Company, to a “C” corporation to be known as FemPulse Corporation. This conversion positions the company for accelerating growth and development of its commercial operations. All LLC members converted their member interests into shares in FemPulse Corporation.